Bone metastases from malignant melanoma: a retrospective review and analysis of 28 cases

Elias Brountzos¹, Irene Panagiotou², Dimitrios Bafaloukos², Dimitrios Kelekis¹

¹Second Department of Radiology, Medical School, Athens University, Eugenidion Hospital, Athens, Greece, ²Second Department of Oncology, Metaxa Cancer Hospital, Piraeus, Greece

Background. The aim of the study was to evaluate the clinical characteristics, the radiological findings, and the treatment effect on the patients with bone metastases from malignant melanoma.

Patients and methods. Retrospective review of 293 stage IV melanoma patients during a 15-year period was made.

Results. Twenty-eight patients (9.5%) with bone metastases were identified; all patients had a thick or intermediate primary melanoma (Breslow 2.7-9.9). Most of the patients presented with multiple (95.6%), symptomatic (92.6%) skeletal lesions. Imaging depicted 90 bone lesions. Axial metastases were more common (86%); 54% of them were located at the spine. Skeletal radionuclide scintigraphy was non-specific; radiography and computed tomography was diagnostic. Typical bone metastases were osteolytic (92.5%). Sixty-six lesions were treated with radiotherapy; in 79% there was a palliative response. There was no correlation between total dose or fraction size and effective palliation. The skeletal lesions did not respond to concurrent chemotherapy and/or bisphosphonates. Median response duration to treatment was estimated to 2.6 months and median survival to 4.7 months.

Conclusions. Osseous metastases from malignant melanoma occur in the patients with more advanced primary lesions. They are most frequently osteolytic and located in the axial skeleton. Radiography and computed tomography is diagnostic. Radiotherapy still remains the treatment of choice.

Key words: bone neoplasms; malignant melanoma, bone metastases; imaging; radiotherapy

Introduction

In most clinical series bone metastases from malignant melanoma are less frequent, ranging from 11%-17%. Nevertheless, the autopsy series have revealed that skeletal involvement is more common (23-49%).

Skeletal metastases generally occur in patients with widespread metastatic disease and usually represent a late site of recurs-
Median survival is estimated to 2-6 months. The aim of our study was to present our experience concerning this uncommon site of melanoma dissemination. We retrospectively evaluated the clinical course, the radiological abnormalities and the response to treatment in this subgroup of melanoma patients.

**Patients and methods**

We reviewed the records of all patients with stage IV malignant melanoma treated in the 2nd Department of Medical Oncology in Metaxa Cancer Hospital from 1985 to 2000. We recorded the patients with disseminated bone disease. The inclusion data were the following: age, sex, location and thickness of primary tumor, time interval between primary tumor and bone metastases, distribution of metastases, location of the metastatic lesion, and presenting signs and symptoms.

Table 1. Characteristics of our patients’ population

| Age at AJCC stage IV diagnosis, years (Median, range) | 50, 26 - 86 |
| Male (%) | 59 |
| Female (%) | 41 |
| Site of primary melanoma (%) | | |
| Lower extremity | 14.1 |
| Upper extremity | 11.1 |
| Trunk | 33.3 |
| Head & neck | 37.8 |
| Unknown origin | 3.7 |
| Breslow’s thickness, mm (Median, range) | 4.1, 2.7 - 9.9 |
| Stage III diagnosed prior to stage IV (%) | 70 |
| Adjuvant treatment before stage IV (%) | 22.2 |
| Disease free interval before stage IV, months (median, range) | 37, 0 - 267 |
| Bone metastases as sole & initial site (%) | 3.7 |
| Multiple bone metastases (%) | 95.6 |

Statistical analysis was performed using the chi-squared test for the correlation between primary melanoma’s thickness and the development of bone metastases. In the comparison, statistical significance was determined using a p-value level of 0.001.

**Results**

From a total of 293 patients with stage IV malignant melanoma, 28 patients (9.5%) with skeletal metastases were identified. The disease dissemination was diagnosed in all 293 patients using computed tomography of the chest and/or abdomen: all patients were submitted to computed tomography during regular follow-up or were evaluated with computed tomography when they became symptomatic. Table 1 shows the 28 patients’ characteristics.

All our patients’ primary melanomas were thick or intermediate (Breslow’s thickness ranging from 2.7-9.9). From the 293 stage IV patients, 165 had a thick or intermediate primary melanoma. When correlated, statistical significance was found (p<0.001). Additionally, most patients (70%) had AJCC stage III disease before the diagnosis of bone metastases.

Twenty-six patients presented with symptoms of bone metastases at the time of the diagnosis: bone pain (85.1%), pathologic frac-
tures (14.8%) and/or bone marrow infiltration (7.4%) were the most common findings. Four patients (14.8%) presented with hypercalcaemia. There were no compression fractures or neurological symptoms. Only 2 patients (7.4%) were asymptomatic; in these patients, skeletal involvement was found during routine abdominal computed tomography.

In all 28 patients, thoracic and/or abdominal computed tomography was initially performed, followed by skeletal radionuclide scintigraphy in the 26 symptomatic patients, and skeletal survey radiographs in 14. Computed tomography of the appendicular skeleton was performed in 9 symptomatic patients, and MRI of the painful skeletal site in 5 patients. All studies yielded positive results. A total of 90 metastatic bone lesions were depicted.

Table 2 shows the distribution of the lesions: axial metastases were more common (86%) than appendicular bone metastases; the lesions were located more commonly at the spine, particularly at the thoracic and lumbar vertebrae.

Table 3 demonstrates the radiological features found in radiographs and computed tomography. More than 90% of the lesions were osteolytic. A mixed osteolytic-osteoblastic pattern was uncommon (Figure 1). We found

<table>
<thead>
<tr>
<th>Location</th>
<th>Percentage of lesions (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spine</td>
<td>54</td>
</tr>
<tr>
<td>Pelvis</td>
<td>21</td>
</tr>
<tr>
<td>Ribs</td>
<td>11</td>
</tr>
<tr>
<td>Femur &amp; tibia</td>
<td>7</td>
</tr>
<tr>
<td>Humeral, ulna &amp; clavicle</td>
<td>4</td>
</tr>
<tr>
<td>Temporal, maxilla &amp; mandible</td>
<td>3</td>
</tr>
</tbody>
</table>

Figure 1. An unusual mixed osteolytic-osteoblastic metastatic pattern located at the lumbar vertebrae.
that 91.1% of the lesions had a medullary origin. Scintigraphy uniformly depicted metastatic lesions as sites of increased uptake of Tc-99m. Magnetic resonance imaging was more specific in depicting the soft-tissue involvement.

Whenever imaging follow-up was performed to evaluate the response to treatment, certain radiological response patterns were identified. Recalcification, sclerotic rim and periostal reaction were the most common findings.

The 66 bone lesions -found in the 26 symptomatic patients - were treated with irradiation, and showed an effective palliative response rate of 79% (52/66). Table 4 demonstrates that the palliation of bone metastases was not related to total dose or fraction size.

In 18 (of the 26) symptomatic patients, 31 symptomatic bone lesions were treated with radiotherapy and concurrent chemotherapy and/or biphosphonates, while 15 asymptomatic lesions were treated only with chemotherapy and/or biphosphonates. Systemic chemotherapy was also given to the two asymptomatic patients with the metastatic lesions at the lumbar vertebrae. In all 20 patients, the disease progressed in extraskeletal sites. As shown in imaging follow-up, 61% of the symptomatic lesions responded to therapy; all of them were clinically palliated. All asymptomatic lesions treated with chemotherapy and/or biphosphonates did not respond radiologically or clinically, but progressed.

Median response duration to treatment was estimated to 2.6 months and median overall survival was estimated to 4.7 months.

Discussion

In our study, only 9.5% of the stage IV melanoma patients had skeletal involvement. A similar low percentage of antemortem diagnosis of bone metastases from malignant melanoma is reported in the literature. Since clinical diagnosis of skeletal involvement is infrequent, little has been published describing the pattern and natural history of melanoma metastatic to the bone.

The limitation of our study is that we did not perform routine screening, so we do not know the exact incidence of skeletal metastases. Based on melanoma surveillance guidelines, our patients were not routinely submitted to bone radionuclide scintigraphy. Nevertheless, we evaluated our patients during the follow-up with chest and abdominal computed tomography, so we were able to detect the majority of skeletal metastases. Melanoma bone metastases occur more frequently in the axial skeleton, and are therefore easily diagnosed by computed tomography. Nevertheless, the real incidence of
osseous disease might be slightly higher than 9.5%, since appendicular bone metastases could not be depicted by thoracic and abdominal computed tomography.

Only 3.7% of our patients had bone metastases as the first and only site of recurrence; the rest of the patients had widespread disease in multiple metastatic sites. This is also in agreement with the literature.\textsuperscript{5}

In our series, skeletal metastases were more frequent in patients with primary melanomas of the trunk and the head and neck area.

We also found that all patients with bone metastases had a thick or intermediate primary melanoma (p<0.001). Additionally, most patients had stage III disease prior to the development of skeletal metastases. Our findings may suggest that the patients with more advanced primary lesions are more likely to develop bone metastases, and should be more closely monitored.

Only 7.4% of our patients were asymptomatic and the skeletal involvement was found during routine imaging follow-up. The metastatic disease was located at the lumbar vertebrae and was detected by an abdominal computed tomography. In our series, axial metastases (86%) were more common than appendicular bone metastases and 54% of them were located in the spine. Our findings are similar to those previously reported, and suggest that whenever a computed tomography is performed to evaluate metastatic melanoma, the axial skeleton should be carefully examined.\textsuperscript{8,9}

Bone radionuclide scintigraphy was nonspecific; all metastatic lesions were depicted as sites of increased uptake of Tc-99m. Plain radiographs and computed tomography images were diagnostic. In the literature, there are few reports of the imaging findings of skeletal melanoma metastases.\textsuperscript{9-11} In our series, melanoma bone metastases were osteolytic with medullary origin. Lesion growth caused cortical erosion and destruction, pathologic fractures and soft-tissue involvement. Atypical skeletal metastases exhibited a mixed osteolytic-osteoblastic pattern or, even more infrequently, a completely osteoblastic pattern. Magnetic resonance imaging better depicted the extent of soft-tissue involvement.

The response assessment of bone metastases to therapy is difficult; in most cases, decisions about the efficacy of treatment are based on symptomatic response or change in extraskeletal metastatic disease. In our study, radiographs and computed tomography were useful in evaluating the tumor’s response to treatment.

One could argue that since the real incidence of bone metastases in clinical series is low, the role of computed tomography or other imaging studies is only complementary. Nevertheless, we showed that serial radiographs or computed tomography are essential in establishing the diagnosis, guiding the treatment planning and assessing the tumor’s response to treatment.

In our series, radiotherapy offered an effective palliation rate of 79%. We believe that it still represents the treatment of choice in this subgroup of patients; the treatment with chemotherapy and/or biphosphonates did not appear as effective. We agree with Rate and al. that concurrent chemotherapy has no influence on palliation.\textsuperscript{12} We found that in palliative treatment of bone lesions from melanoma, the application of high total dose or high fraction size was not advantageous at all. High doses should be avoided since they do not offer more effective palliation and can create greater complications. Similar results were reported by Konefal et al.\textsuperscript{13} in the analysis of dose fractionation in the palliation of bone and brain metastases from malignant melanoma.

Despite the palliation offered with radiotherapy, our patients’ prognosis was poor. Median survival was similar to the one previously reported in the literature\textsuperscript{1,2,5} and esti-
mated to 4.7 months. Even if patients with thick or intermediate primary cutaneous melanomas could be more closely monitored in order to detect asymptomatic bone metastases, no change in palliation or survival would be achieved.

In conclusion, we recommend a skeletal evaluation with radiographs or computed tomography - whenever symptoms develop - and a careful examination of the axial skeleton in the patients with advanced primary melanomas. The life expectancy of these patients is short, but conventional fractionation radiotherapy can offer effective palliation to most of these patients. It is therefore worthwhile to pursue the diagnosis.

References